Quickly find dozens of antibodies
Quickly find dozens of antibodies
Quickly find dozens of antibodies
OVERVIEW
With over 100,000 different GPCR binding motifs, unlock the discovery of antibodies to this
difficult-to-target class.
GPCRs are Hard-to-Drug
-
30-50% of current drug targets are GPCRs but there are only 2 FDA approved antibodies
-
Current antibody drug development methods do not work
- Random mutagenesis libraries are too inefficient to explore the effective sequence space
Synthetic Library Advantage
- No immunization required
- Synthetic mAb libraries focus on effective sequence space
- Simultaneous screening against multiple targets
> 100,000 Different GPCR binding motifs
Chemokines
Helical peptides
Looped peptides
GPCR ECD1 & ECL2
Anti-GPCR antibodies
With over 100,000 different GPCR binding motifs, unlock the discovery of antibodies to this
difficult-to-target class.
GPCRs are Hard-to-Drug
-
30-50% of current drug targets are GPCRs but there are only 2 FDA approved antibodies
-
Current antibody drug development methods do not work
- Random mutagenesis libraries are too inefficient to explore the effective sequence space
Synthetic Library Advantage
- No immunization required
- Synthetic mAb libraries focus on effective sequence space
- Simultaneous screening against multiple targets
> 100,000 Different GPCR binding motifs
Chemokines
Helical peptides
Looped peptides
GPCR ECD1 & ECL2
Anti-GPCR antibodies
PROOF OF CONCEPT
Multiple Antibodies Bind GLP1R Over-Expressing CHO Cells and are Functional in a cAMP Assay
- IgGs are monomeric and not prone to aggregation
- Multiple FACS positive hits include GLP-1 and GLP-2 motifs as well as
additional unique sequences.
Multiple Antibodies Bind GLP1R Over-Expressing CHO Cells and are Functional in a cAMP Assay
- IgGs are monomeric and not prone to aggregation
- Multiple FACS positive hits include GLP-1 and GLP-2 motifs as well as
additional unique sequences.
RESOURCES
